Tirzepatide (mounjaro) 5mg 10mg 15mg allura

Tirzepatide

Tirzepatide bincike ne sau ɗaya-mako-mako, dual glucose-dogara insulinotropic polypeptide da glucagon-kamar peptide-1 agonist mai karɓa wanda ke haɗa ayyukan duka incretin a cikin kwaya ɗaya.

Tirzepatide Yana Mimics Na Halitta Hormones waɗanda ke Ba da Cikakkun Ji
Tirzepatide yana aiki ta hanyar kwaikwayon GLP-1 da GIP hormones waɗanda hanji ke ɓoye ta hanyar dabi'a bayan cin abinci, wanda ke haifar da ɓoyewar insulin.Hakanan yana rage ci ta hanyar rage lokacin da yake ɗaukar ciki zuwa fanko da yin hulɗa tare da wuraren da ke cikin kwakwalwar masu karɓar GLP-1 don nuna gamsuwa.

Tirzepatide sabon magani ne wanda aka amince da FDA don kula da nau'in ciwon sukari na 2.Idan aka yi la’akari da kaddarorin sa na asarar nauyi.tirzepatidea yi amfani da alamar kashe-kashe don maganin kiba.Yana aiki azaman dual GLP-1 agonist da GIP agonist don haɓaka fa'idodi iri ɗaya waɗanda ake gani tare da magungunan GLP-1 kamar semaglutide.A halin yanzu ana aiwatar da shi azaman maganin ciwon sukari na layi na biyu, kama da magungunan GLP-1, kuma ana ba da shi azaman allurar subcutaneous sau ɗaya a mako.

Tirzepatide shine mai karɓar insulinotropic polypeptide (GIP) mai dogaro da glucose da glucagon-kamar peptide-1 (GLP-1) recepto agonist, wanda FDA ta amince da shi don kula da nau'in ciwon sukari na 2.Yana da mahimmanci a lura cewa ba a yarda da tirzepatide don kula da nau'in ciwon sukari na 1 ba kuma ba a yi nazarin marasa lafiya da pancreatitis ba.Tirzepatide shine mai karɓar GIP da GLP-1 agonist mai karɓa, wanda ke haifar da ingantaccen sarrafa glycemic a cikin nau'in ciwon sukari na 2 da raguwar nauyi.

FDA ta amince da Tirzepatide a watan Mayu 2022. Hakanan ana iya amfani da tirzepatide a kashe-lakabin don magance kiba.A halin yanzu ana aiwatar da shi azaman maganin ciwon sukari na layi na biyu, kama da magungunan GLP-1 kamar semaglutide.Magani ne na allurar subcutaneous sau ɗaya a mako tare da ƙara yawan kashi.

Bayanan asibiti na yanzu sun nuna cewa tirzepatide ya fi placebo a inganta matakan haemoglobin A1C.Gwajin gwaji na SURPASS-5 ya nuna -2.11% raguwa a matakan haemoglobin A1C a 5mg a kowace mako, idan aka kwatanta da -0.86% tare da placebo.A mafi girman kashi na 15 MG kowace mako, tirzepatide ya haifar da raguwa -2.34% a cikin haemoglobin A1C.An nuna hakan sama da makonni 40.An ga raguwar nauyin kilogiram 5.4 tare da 5mg na tirzepatide dosing, kuma an ga raguwar kilogiram 10.5 tare da kashi 15 na MG.Wannan alaƙar dogaro da kashi tare da asarar nauyi yayi kama da semaglutide, magani na GLP-1 na gama gari da ake amfani da shi don sarrafa asarar nauyi.

Kwatanta, an nuna tirzepatide yana aiki daidai da magungunan GLP-1 amma tare da inganci.Idan aka yi la'akari da kaddarorinsa na asarar nauyi da rashin gubar hanta, yana yiwuwa ya taka rawar kai tsaye wajen magance cutar hanta mai ƙiba (NAFLD) kuma.

NOTE

Muna jigilar kaya a duk duniya.
Ana ba ku shawarar tuntuɓar shawarwarin likitan ku kafin amfani da samfurin.